Almaral is proud to be a companion on OrlaDTx’s, one of our portfolio companies, journey to become one of the leading companies in digital therapeutics. We talked with Tuomas Mäkynen, the CEO of OrlaDTx about Almarals and Orlas past, current and future relations.
How has Almara offerings supported Orla?
Mäkynen: “Almaral’s support is evident in discussions about Orla’s growth and its demands. Almaral combines long-term international business expertise and health technology expertise, which brings both depth and a broad perspective to the creation of a growth base, and provides a good starting point for long-term and strongly believing in successful cooperation.”
In what way has Almaral helped you tackle obstacles that Orla has faced this far?
Mäkynen: ”Finding an investor that adds value to Orla’s development has been paramount. This includes having a shared vision of healthcare’s future and a commitment to solving major challenges through impactful, scalable innovations. With an experienced founding team, Orla appreciates Almaral’s expertise in international business development. Amidst challenging financing markets for growth companies, collaborating with a value-adding investor enhances our competitiveness.”
How has Almaral contributed to Orlas achievement of its objectives?
Mäkynen: “Interactions with Almaral have refined Orla’s growth strategy and goals. We value Almaral’s commitment, collaborative learning approach, and proactive interest in our development. Their extensive partner network can be beneficial in our joint journey.”